Ipamorelin for Muscle Gain: Protocol, Dosing, and What to Expect

What this protocol is for

Ipamorelin is the GHRP (growth-hormone-releasing peptide) half of the canonical GH stack. Mechanism: it binds the ghrelin receptor in the pituitary and triggers a clean growth hormone pulse without the cortisol or prolactin elevation that older GHRPs (GHRP-2, GHRP-6) produce. That clean signal is what makes Ipamorelin the default GHRP for hypertrophy work. Stacked with a GHRH analog like CJC-1295 (which acts on a different receptor), the two compounds produce a meaningfully larger combined GH pulse than either alone, which feeds the IGF-1 elevation that drives lean-tissue gains.

The clinical pattern is consistent across user reports. Lifters past peak puberty whose natural GH curve has flattened. Men running a hard hypertrophy block who want every recovery advantage. Returning sportsmen rebuilding lean mass after a long layoff. Anecdotally, users report 1 to 2 kg of lean mass over an 8 to 12 week cycle on top of an already-good training programme, improved sleep, faster between-session recovery, and noticeably better skin and hair as downstream effects of the elevated GH/IGF-1 environment.

Used by many in the recovery / biohacking space alongside CJC-1295 because the stack consistently outperforms either alone. Run this as a tactical, legal performance layer on top of progressive overload, protein intake, sleep, and recovery work. Ipamorelin amplifies the cellular environment; it does not replace the training stimulus.

Dose for muscle gain

100 to 300 mcg subcutaneous per injection, 1 to 3 times daily. The short half-life (~2 hours) means daily-or-multiple-daily dosing is required; this is not a once-weekly molecule. Common rhythm: 200 mcg pre-training, 200 mcg pre-sleep, optionally 200 mcg mid-morning. Stack with CJC-1295 at the same dose per injection for the canonical GH-pulse amplification.

Cycle length

8 to 12 weeks for muscle-gain protocols. Continuous use beyond 16 weeks degrades signal as the pituitary feedback regulation adapts. Cycle off 4 to 6 weeks between runs to preserve responsiveness.

Stack pairings

Commonly stacked with CJC-1295.

Expected timeline

Week 1–3: improved sleep, faster recovery between training sessions, appetite typically increases. Week 4–6: IGF-1 elevation reaches steady-state; training capacity improves. Week 6–12: lean tissue gains land. 1 to 2 kg of lean mass over a full cycle on top of well-built training is the typical range.

Common mistakes

• Running Ipamorelin alone without CJC-1295. Single-receptor GH stimulation under-delivers; the GHRH plus GHRP stack consistently produces a larger pulse. Most protocols use both.
• Dosing once daily and expecting a hypertrophy-tier result. The short half-life requires multiple daily injections for meaningful steady-state effect. Twice daily minimum, three times for serious hypertrophy work.
• Treating the protocol as a substitute for the training block. The peptide amplifies the cellular environment; the training and protein intake drive the actual hypertrophy direction.
• Ignoring the appetite increase. Ghrelin-receptor binding elevates hunger. Track protein intake; control discretionary calories or the body composition outcome drifts toward fat gain rather than lean tissue.
• Mixing Ipamorelin with older GHRPs (GHRP-2, GHRP-6) on the same protocol. The cleaner signal from Ipamorelin is the reason it is the default GHRP. Stacking older GHRPs adds cortisol and prolactin elevation and loses the cleanliness.